Monoclonal Antibody Approaches to Cancer Therapy

Monoclonal antibody
approaches to cancer therapy

Introduction
Monoclonal antibodies are higher essential in triggering specific rise in individuals
immune system within body, which further develops response which has significant impact on
destroyed outer wall membrane in cancer cell. Monoclonal antibodies trigger immune system
responses immediately, which destroys outer wall of cancer cell, blocking cell growth effectively
for stopping spread of cancer. It further blocks connection between cancer cell and proteins, and
also primitively improvises body response to cancer. Bevacizumab is medication, used to treat
number in varied types of cancers within medical science and specific eye disease where it is
given by slow injection into veins. It is also used for colon cancer, within medical science.
Research will examine focus on usage of bevacizuma, monoclonal antibodies in cancer therapy
and comparison from traditional approaches such as chemotherapy and radiotherapy. Study will
discuss mechanism of action, benefits of existing therapeutic strategies used for cancer and
varied disadvantages related to taking monoclonal antibodies.
Use of Monoclonal antibody- Bevacizumab in cancer therapy
As per the views of Nasu and et.al, (2022), Bevacizuma is one of the most effective
monoclonal antibody used within treatment of cancer, which targets specific cancer cell protein
called vascular endothelial growth factor. It helps cancer to grow blood vessels, to stop growth of
cancer cells in body which is one of the most effective aspect found in antibodies. Research by
author explains that Bevacizuma is used to treat medical cancer of colon (large intestine), rectum
that has spread into body. It is used to treat lung cancer which spread into nearby tissues, that
cannot be removed by surgeries or therapies. It can be also analysed that Bevacixuma works
differently from traditional treatment chemotherapy, where it holds huge significance with
implementation of new technology.
The specific purpose of Bevacixuma is related to prevent growth of new blood vessels
within body, where this specifically includes normal vessels and blood vessels that fed tumours.
It has been approved for treatment of colorectal cancer, where it further has been approved for
treating lung cancer. Bevacixuma treats glioblastoma, which has been improved or has come
back after treatment with previous taken medications.. Combination with other chemotherapy

medications, enables to treat cervical cancer, that begins with opening of uterus. It is humanized
monoclonal antibody directed against circular vascular growth factor, where it has vitally
become first anti-angiogenic agent, which has been found to be approved by US drug
administration for treatment of cancer. Also, Monoclonal antibody has been found to be highly
crucial for improvising further extensive improvement in patient health condition in proper
timely format.
Comparison from traditional approaches such as chemotherapy and radiotherapy
As noted by Ambrosin. and et.al (2022), in comparison of Bevacixuma, with traditional
approaches such as chemotherapy and radiotherapy, there is effective new advanced treatment
with usage of new of technology. Chemotherapy leads to gum sores, gastrointestinal problems
and skin change in cancer patients. There is change in individual weight, physical symptoms
along with prolonged sickness and hair loss by taking chemotherapy. Research in recent study
has shed light on fact that Bevacixuma has very less side effects in comparison with traditional
chemotherapy treatments. This explains Bevacixuma us has been found to be effective, and also
further bringing timely improvement in cancer patients condition.
Also monoclonal antibody, blocks connection found within between cancer cell and
proteins structure that promote cell growth which is specific activity that is necessary for
survival. In comparison with traditional chemotherapy treatments for cancer, there is anaemia,
nausea and vomiting experienced by patients. Also there is appetite changes found along with
constipation, with chemotherapy treatment within patients conditions which lowers better long
term improvement in recovery. There are cognitive difficulties, hearing problems and increased
risk of blood clotting along with lung problems and reproductive changes. When compared with
usage of Bevacixuma, chemotherapy is highly long term duration treatment of cancer. It also
often leads to depressive mental conditions, where this hampers specific living conditions for
gaining medical recovery within long term recovery period.
As per the views of .Renpen and et.al, (2022), author critically argues Bevacizumab
prevent blood vessels from reaching tumour, where it starves the tumour for second line
treatment after first line treatment. The use of new advanced technology, within monoclonal
antibody approach to cancer therapy has numerous benefits for patients as compared with
chemotherapy traditional treatment. Bevacizumab, is widely effective for further improvised
treatments of cancer patient and also found to be improved on for timely healing.